- Home
- CMS vs PODD Comparison
CMS vs PODD Comparison
Compare CMS & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMS | PODD |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 22.1B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | CMS | PODD |
|---|---|---|
| Price | $71.41 | $304.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $79.00 | ★ $359.00 |
| AVG Volume (30 Days) | ★ 2.2M | 765.6K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.47 | 3.45 |
| Revenue | ★ $8,295,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | $9.21 | $32.55 |
| Revenue Next Year | $3.75 | $20.39 |
| P/E Ratio | ★ $20.49 | $88.24 |
| Revenue Growth | 10.96 | ★ 27.11 |
| 52 Week Low | $63.97 | $230.05 |
| 52 Week High | $76.45 | $354.88 |
Technical Indicators
Market Signals| Indicator | CMS | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 40.94 |
| Support Level | $71.01 | $303.20 |
| Resistance Level | $75.46 | $317.34 |
| Average True Range (ATR) | 1.03 | 13.12 |
| MACD | -0.37 | -2.82 |
| Stochastic Oscillator | 2.13 | 3.14 |
Price Performance
Historical ComparisonAbout CMS CMS Energy Corporation
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.